Anzeige
Meldung des Tages: Goldaktie mit Nachholpotenzial: Über 2 Mio. Unzen Gold – und trotzdem erst 59 Mio. USD Börsenwert?

Lipocine Aktie News

Aktie
WKN:  A3EBZD ISIN:  US53630X2036 US-Symbol:  LPCN Land:  USA
9,00 $
+0,13 $
+1,47%
7,5946 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
23,77 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Lipocine News

20.01.26 - PR Newswire
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire
12.01.26 - PR Newswire
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire
16.12.25 - PR Newswire
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PR Newswire
18.11.25 - PR Newswire
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire
06.11.25 - PR Newswire
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 PR Newswire
04.11.25 - PR Newswire
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® PR Newswire
30.09.25 - PR Newswire
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) PR Newswire
05.09.25 - PR Newswire
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
26.08.25 - PR Newswire
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 PR Newswire
05.08.25 - PR Newswire
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 PR Newswire
26.06.25 - PR Newswire
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression PR Newswire
23.06.25 - PR Newswire
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 PR Newswire
09.06.25 - PR Newswire
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada PR Newswire
22.05.25 - PR Newswire
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology PR Newswire
14.05.25 - PR Newswire
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase PR Newswire
08.05.25 - PR Newswire
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 PR Newswire
06.05.25 - PR Newswire
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil PR Newswire
26.03.25 - PR Newswire
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 PR Newswire
13.03.25 - PR Newswire
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 PR Newswire
12.03.25 - PR Newswire
Lipocine Announces FDA Labeling Changes for Testosterone Products
Lipocine Announces FDA Labeling Changes for Testosterone Products PR Newswire

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »
Anzeige

Aktie im Fokus

Durchbruch bei Drohnen-Batterien
NEO Battery Materials Ltd
0,39 €
-3,94%
NEO Battery Materials Ltd Chart
Diese Nachricht schockt den Markt
Mehr zur Aktie »